Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Study Finds Significant Response of Nivolumab-Refractory Lung Cancer to Salvage Chemotherapy

Alison Rodriguez
Physicians should be cautious when treating patients with lung cancer after progression on nivolumab because nivolumab-refractory lung cancer could have a significant response to salvage chemotherapy, according to a new study.
Physicians should be cautious when treating patients with lung cancer after progression on nivolumab because nivolumab-refractory lung cancer could have a significant response to salvage chemotherapy, according to a new study.

Although salvage chemotherapy after nivolumab therapy has demonstrated potential efficacy, there is minimal information on the clinical and immunologic features in lung cancer patients where the treatment is unsuccessful.

In a new study, published in Thoracic Cancer, the researchers hypothesized that chemotherapy improved the balance between immunostimulator and immunosuppressive cells to synergize with the immunostimulatory effects of the previous nivolumab treatment. In order to test this, the researchers conducted 2 case reports with 2 nivolumab refractory lung-cancer patients.

The first patient was a 66-year-old female, current smoker, who was diagnosed with stage IV undifferentiated non-small cell lung cancer (NSCLC) with bone metastasis. Her treatment was not successful and, following an additional 6 cycles of nivolumab, disease progression still occurred. However, when the nivolumab treatment regimen changed to the oral chemotherapy S-1 at a dose of 60 mg twice daily for 28 days, the tumor regressed and the patient remained progression-free for 5 months.

“Although the definition and exact mechanisms of pseudoprogression following nivolumab therapy remain undetermined, we considered this possibility in our cases. In Case 1, the tumor enlarged and respiratory symptom worsened after the 18-week observation period during nivolumab therapy,” the authors noted. “On review of previous clinical trials for NSCLC, symptomatic pseudoprogression was uncommon at nine weeks after the initiation of nivolumab.”

The second case report was a 75-year-old man who was a former smoker and diagnosed with stage IIIA lung adenocarcinoma with pulmonary metastases. The patient’s treatment, including chemotherapy were not originally successful and after 6 cycles of nivolumab, disease progression was evident. When the patient’s treatment changed to carboplatin/albumin-bound paclitaxel, his tumor rapidly regressed.

“In conclusion, physicians should be cautious when treating patients after progression on nivolumab because nivolumab-refractory lung cancer could show a remarkable response to salvage chemotherapy,” the study concluded.

The study calls for further research with a larger cohort to determine the extent of benefits of salvage chemotherapy and how the responders are selected.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!